FDA Drug Safety Committee To Discuss Use Of Post-Marketing Studies May 19
This article was originally published in The Pink Sheet Daily
Executive Summary
The Drug Safety & Risk Management Advisory Committee will consider the utility of various types of post-market studies in detecting and quantifying risk.